MedPath

Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Public
Established
2007-01-01
Employees
4
Market Cap
-
Website
http://www.ipharminc.com

Clinical Trials

5

Active:0
Completed:5

Trial Phases

2 Phases

Phase 1:1
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (80.0%)
Phase 1
1 (20.0%)

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Placebo
Drug: Standard of Care (SoC)
First Posted Date
2021-03-05
Last Posted Date
2022-09-16
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
120
Registration Number
NCT04784897
Locations
🇷🇺

IPI Investigator Site, Saint Petersburg, Russian Federation

A Study to Investigate the Use of Delayed Release Tablets for Colonic Delivery of Brilacidin in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
Radiation: 4Mq 99mTc-DTPA
First Posted Date
2020-01-27
Last Posted Date
2020-02-24
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
9
Registration Number
NCT04240223
Locations
🇬🇧

BDD Pharma Ltd, Glasgow, Scotland, United Kingdom

A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
First Posted Date
2017-02-03
Last Posted Date
2018-12-27
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
2
Registration Number
NCT03042702
Locations
🇺🇸

Cancer Research, Dallas, Texas, United States

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Chronic Stable Plaque Psoriasis
Interventions
Drug: Placebo
Drug: 300 mg (150 mg BID)
Drug: 400 mg (200 mg BID)
First Posted Date
2016-10-31
Last Posted Date
2018-02-13
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
199
Registration Number
NCT02949388
Locations
🇺🇸

Study Site, Webster, Texas, United States

🇺🇸

Study Center, Charlottesville, Virginia, United States

🇺🇸

Clinical Study Site, San Antonio, Texas, United States

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

Phase 2
Completed
Conditions
Head and Neck Neoplasms
Mucositis
Interventions
Other: Placebo
First Posted Date
2014-12-24
Last Posted Date
2019-01-16
Lead Sponsor
Innovation Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT02324335

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.